PUBLISHER: Grand View Research | PRODUCT CODE: 1611184
PUBLISHER: Grand View Research | PRODUCT CODE: 1611184
The global DNA microarray market size is expected to reach USD 3.53 billion by 2030, registering CAGR of 8.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. The DNA microarray market is anticipated to witness exponential growth opportunities owing to the technological advancements and rising R&D investments by the leading participants. In addition, the increasing adoption of DNA microarray technologies in various applications such as genetic disease diagnosis, cancer research, and personalized medicine are the leading factors propelling the global market.
Rapid and accurate disease diagnosis is very crucial for the appropriate treatment of the patients. The recent advances in molecular-level interaction & detection technologies are upgrading clinical diagnostics services by offering novel solutions for diagnosis. Likewi se, the recent advancements in diagnostic DNA microarrays have opened new avenues for the market stakeholders. The DNA microarray technique has applications in genotyping, disease diagnosis, detecting abnormalities, and screening nucleotide polymorphisms.
Moreover, the global DNA microarray market is anticipated to witness exponential growth opportunities owing to the increased research funding, rising healthcare costs, technological advancements, and increased demand for the precision and tailored therapeutic solutions. For instance, according to Med City INVEST Precision Medicine, consumers are increasingly aware of the specific therapies, including precision therapy for treating chronic diseases.
In addition, increased investments by the leading players in the production of effective and advanced diagnostic tools and various strategic initiatives undertaken by the market participants are likely to create new avenues for expansion. For instance, in September 2022, Illumina, Inc. announced the launch of the NovaSeq X Series, a next-generation technology product that can produce more than 20,000 genomes per year. In addition, in September 2021, SCHOTT MINIFAB acquired an Arizona-based microarray solutions company. This acquisition is expected to help the company to strengthen its bioscience capabilities in the U.S.